2/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

UNITED STATES LIFE SCIENCES 2022

WELCOME LETTER

Welcome to the 2022 edition of the United States Life Sciences Industry Report. After two years of fighting Covid-19, the United States has offered a glimpse of what the industry may look like in a post-pandemic world. Compared with the investment frenzy that led to a peak in capital inflow into the industry in early 2021, the financial climate has cooled considerably. The ensuing period of dramatic correction has forced companies to work harder to prove their worthiness of investors’ dollars. Within this context, it is increasingly small and mid-sized companies claiming ownership to the development pipeline and commercialization of new drugs. Tireless advances have been made across a variety of fields, such as gene editing and cell-based therapies, as well as in the introduction of novel drug delivery platforms and diagnostics tools. These efforts culminated in 50 new drug approvals in 2021, in line with the past five years of consistently strong output. Of course, the magnitude of success does not rest squarely on the shoulders of only pharmaceutical and biopharmaceutical companies – contract service providers are crucial to the health of the life sciences ecosystem. Responding to the heightened complexity of the field, the explosion of streamlined companies with modern in-house manufacturing capabilities, and an industry-wide rallying cry for increased domestic production, CROs and CDMOs are stepping up to create a more robust environment. The following pages bring together insights from interviews conducted with over 80 industry leaders whose experiences collectively span all areas of the sector. We would like to warmly thank these executives and researchers whose thoughtful contributions were invaluable to the report as well as our association partners at BioNJ and Biocom California. We hope that you enjoy reading our 2022 edition of the United States Life Sciences Industry Report.

SECTIONS

Image courtesy of Vetter Pharma

Next:

Article & Interview Directory